Abstract 13854: Comparative Efficacy and Safety of Aldosterone Synthase Inhibitors versus Mineralocorticoid Receptor Antagonists for Resistant Hypertension: A Systematic Review and Network Meta-Analysis
Introduction: Resistant hypertension often persists despite multidrug therapy, driven by unopposed aldosterone activity. In May 2026, the FDA approved baxdrostat, a first-in-class aldosterone synthase inhibitor. Other agents include mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone....